Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Leukemia 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Gastrointestinal Stromal Tumors 13Leukemia, Myeloid, Chronic-Phase 12Leukemia, Myeloid 6Brain Neoplasms 6Prostatic Neoplasms 5Philadelphia Chromosome 5Blast Crisis 5Sarcoma 4Recurrence 4Glioblastoma 4Carcinoma, Non-Small-Cell Lung 4Bone Marrow Diseases 4Ovarian Neoplasms 3Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Breast Neoplasms 3Stomach Neoplasms 2Polycythemia Vera 2Neurofibromatoses 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Meningioma 2

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Uterine Sarcoma × Imatinib Mesylate × Clear all
NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡